JP2019513126A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513126A5 JP2019513126A5 JP2018545900A JP2018545900A JP2019513126A5 JP 2019513126 A5 JP2019513126 A5 JP 2019513126A5 JP 2018545900 A JP2018545900 A JP 2018545900A JP 2018545900 A JP2018545900 A JP 2018545900A JP 2019513126 A5 JP2019513126 A5 JP 2019513126A5
- Authority
- JP
- Japan
- Prior art keywords
- ethoxy
- amino
- xaa
- acetyl
- chem
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C(c(cc1)ccc1OCCCCCCCC=O)=O Chemical compound *C(c(cc1)ccc1OCCCCCCCC=O)=O 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16158388.5 | 2016-03-03 | ||
| EP16158388 | 2016-03-03 | ||
| PCT/EP2017/054895 WO2017149070A1 (en) | 2016-03-03 | 2017-03-02 | Glp-1 derivatives and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019513126A JP2019513126A (ja) | 2019-05-23 |
| JP2019513126A5 true JP2019513126A5 (enExample) | 2020-04-09 |
| JP7053480B2 JP7053480B2 (ja) | 2022-04-12 |
Family
ID=55451126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018545900A Active JP7053480B2 (ja) | 2016-03-03 | 2017-03-02 | Ｇｌｐ－１誘導体及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10946074B2 (enExample) |
| EP (1) | EP3423481B1 (enExample) |
| JP (1) | JP7053480B2 (enExample) |
| CN (1) | CN108699126B (enExample) |
| ES (1) | ES2835033T3 (enExample) |
| WO (1) | WO2017149070A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020002804A2 (pt) | 2017-08-24 | 2020-07-28 | Novo Nordisk A/S | composição farmacêutica líquida, e, kit |
| SMT202200352T1 (it) | 2018-04-05 | 2022-09-14 | Sun Pharmaceutical Ind Ltd | Analoghi del glp-1 innovativi |
| CN115814063B (zh) * | 2018-04-19 | 2026-07-28 | 杭州先为达生物科技股份有限公司 | Glp-1衍生物及其治疗用途 |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| WO2020104833A1 (en) | 2018-11-19 | 2020-05-28 | 4P-Pharma | Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production |
| CN109730270B (zh) * | 2019-02-12 | 2022-06-28 | 西安培华学院 | 一种降糖酵母发酵南瓜粉及制备方法和应用 |
| IL294521A (en) | 2020-02-18 | 2022-09-01 | Novo Nordisk As | glp-1 compounds and their uses |
| CN118754965A (zh) * | 2020-05-29 | 2024-10-11 | 北京拓界生物医药科技有限公司 | Glp-1和gip受体双重激动剂化合物及其应用 |
| CA3193453A1 (en) | 2020-09-30 | 2022-04-07 | Beijing Ql Biopharmaceutical Co., Ltd. | Polypeptide conjugates and methods of uses |
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| CA3231953A1 (en) | 2021-09-15 | 2023-03-23 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| CN116650424A (zh) * | 2022-01-06 | 2023-08-29 | 鸿绪生物医药科技（北京）有限公司 | 新型多肽制剂及其治疗用途 |
| EP4323413A4 (en) | 2022-03-30 | 2025-10-15 | Beijing Ql Biopharmaceutical Co Ltd | LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF |
| CN114984191B (zh) * | 2022-07-04 | 2022-10-25 | 北京惠之衡生物科技有限公司 | 一种多肽类药物口服递送组合物 |
| WO2026008836A1 (en) | 2024-07-05 | 2026-01-08 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
| US20260015407A1 (en) * | 2024-07-15 | 2026-01-15 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory fusion proteins and related methods |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| DE60038097T2 (de) | 1999-02-22 | 2009-02-12 | Merrion Research I Ltd. | Feste orale dosierungsform enthaltend einen resorptionsverstärker |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| EP2514406A1 (en) | 2007-06-01 | 2012-10-24 | Novo Nordisk A/S | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier |
| EP2190872B1 (en) | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| CN101255191A (zh) | 2008-03-12 | 2008-09-03 | 中国药科大学 | 微波促进固相合成胰高血糖素样肽-1(glp-1)类似物及其应用 |
| US20110306551A1 (en) | 2009-02-19 | 2011-12-15 | Novo Nordisk A/S | Modification of Factor VIII |
| US20120329711A1 (en) | 2009-12-16 | 2012-12-27 | Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| AU2012241894B2 (en) | 2011-04-12 | 2015-12-03 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
| CN102180963B (zh) | 2011-04-22 | 2014-06-25 | 中国药科大学 | 胰高血糖素样肽-1(glp-1)类似物及其应用 |
| CN110041399B (zh) | 2011-12-29 | 2023-12-12 | 诺沃—诺迪斯克有限公司 | 包含非成蛋白质性的氨基酸的二肽 |
| KR102072202B1 (ko) | 2012-03-22 | 2020-01-31 | 노보 노르디스크 에이/에스 | Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조 |
| CN103087178A (zh) | 2012-11-30 | 2013-05-08 | 中国药科大学 | 长效化胰高血糖素样肽-1(glp-1)类似物及其应用 |
| AU2014283221A1 (en) | 2013-06-20 | 2015-12-03 | Novo Nordisk A/S | GLP-1 derivatives and uses thereof |
| JP6139712B2 (ja) | 2013-07-04 | 2017-05-31 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１様ペプチドの誘導体及びその使用 |
| BR112016017402A2 (pt) | 2014-02-21 | 2017-10-17 | Medimmune Ltd | fusões anti-pcsk9~glp-1 e métodos para uso |
| WO2015155151A1 (en) | 2014-04-07 | 2015-10-15 | Novo Nordisk A/S | Double-acylated glp-1 compounds |
| JP6730278B2 (ja) | 2014-11-27 | 2020-07-29 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体及びその使用 |
| EP3233898A1 (en) | 2014-12-17 | 2017-10-25 | Novo Nordisk A/S | Glp-1 derivatives and uses thereof |
-
2017
- 2017-03-02 WO PCT/EP2017/054895 patent/WO2017149070A1/en not_active Ceased
- 2017-03-02 JP JP2018545900A patent/JP7053480B2/ja active Active
- 2017-03-02 ES ES17708491T patent/ES2835033T3/es active Active
- 2017-03-02 US US16/077,759 patent/US10946074B2/en active Active
- 2017-03-02 CN CN201780014939.5A patent/CN108699126B/zh active Active
- 2017-03-02 EP EP17708491.0A patent/EP3423481B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016523243A5 (enExample) | ||
| JP2017105819A5 (enExample) | ||
| JP2016529253A5 (enExample) | ||
| JP2018505859A5 (enExample) | ||
| US10265384B2 (en) | Tablets comprising GLP-1 agonist and enteric coating | |
| JP4228398B2 (ja) | 神経ペプチドｙ受容体拮抗剤 | |
| JP4800959B2 (ja) | 糖尿病及び過食症を治療するためのｇｌｐ−１ペプチド及び短時間作用型インスリンペプチドを含む、非経口投与用の可溶性医薬組成物 | |
| AU2011247824B2 (en) | Glucagon-like peptide-1 analogue and use thereof | |
| JP2014529629A5 (enExample) | ||
| US20220062184A1 (en) | Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release Coating | |
| JP2023071869A (ja) | グルカゴンおよびｇｌｐ－１受容体の長時間作用型コアゴニスト | |
| JP2008533105A5 (enExample) | ||
| RU2007134156A (ru) | Ацилированные glp-1 соединения | |
| JP2017537068A (ja) | グルカゴンおよびｇｌｐ−１受容体のコアゴニスト | |
| RU2652783C2 (ru) | Двойные агонисты glp1/gip или тройные агонисты glp1/gip/глюкагона | |
| JP2022095872A (ja) | ヒトインスリンまたはそのアナログのアシル化誘導体 | |
| RU2007134155A (ru) | Glp-1 соединения с увеличенным временем полужизни | |
| RU2006129299A (ru) | Применение четвертичных солей пиридиния в качестве вазопротекторных средств | |
| CN102026641A (zh) | 并用或组合dpp-iv抑制剂和其它糖尿病治疗药的药品 | |
| RU2020108281A (ru) | Новые ацилированные аналоги инсулина и варианты их применения | |
| US20100305139A1 (en) | Method of treating abnormal lipid metabolism | |
| EP3681529A1 (en) | Mic-1 and glp-1 for use in the treatment of obesity | |
| JP2012529434A5 (enExample) | ||
| JP2020531451A5 (enExample) | ||
| JP2023508349A (ja) | グルカゴン受容体およびｇｌｐ－１受容体のステープルトリアゾールコアゴニスト |